• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Company News
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • Pharmacology
    • Consultancy
    • Medical writing
    • Data management
  • INDICATIONS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
    • Publications
  • WORK WITH US
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Company News
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • Pharmacology
    • Consultancy
    • Medical writing
    • Data management
  • INDICATIONS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
    • Publications
  • WORK WITH US

Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.

Uncategorized 20. April 2020
ShareTwitterFacebookXingLinkedin

This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.

Read Article

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Science 20. April 2020
ShareTwitterFacebookXingLinkedin

Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. I

Read Article

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.

Science 20. April 2020
ShareTwitterFacebookXingLinkedin

We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation.

Read Article
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • INDICATIONS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Work with us
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2021 CRS. Experts. Early Phase. All rights reserved.